drugset

drugset / Trial / NCT00163059

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

NCT00163059 ↗

Phase 2 Completed 30 enrolled Pfizer

RandomizedParallel-groupSingle-blindTreatment

Summary

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Timeline

Start: 2004-05
Primary completion: —
Completion: 2005-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CP-101,606	Unknown	—	—

Indications